GlassScriptPhysician profile
Kolo N Ediale
NPI 1780684738
$20,047.57
in general payments reported to CMS, 2019-2025
36 companies · none reported in 2025
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,908 · 2020: $2,894 · 2021: $3,459 · 2022: $3,501 · 2023: $2,590 · 2024: $697.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,287.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,286.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $3,124.22 | 2019-2024 | Ozempic, Rybelsus, Saxenda |
| Sanofi-Aventis U.S. LLC | $2,137.74 | 2019-2024 | |
| Lilly USA, LLC | $2,024.70 | 2019-2024 | Jardiance, Mounjaro, Baqsimi |
| Amgen INC. | $1,810.70 | 2019-2024 | Evenity, Prolia, Repatha |
| Corcept Therapeutics | $1,311.02 | 2019-2024 | Korlym |
| Astrazeneca Pharmaceuticals LP | $1,071.36 | 2019-2023 | Farxiga, Lokelma |
| Antares Pharma, INC. | $1,056.61 | 2019-2024 | Xyosted, Tlando, Nocdurna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $908.18 | 2019-2024 | Tradjenta, Synjardy, Jardiance |
| Abbvie INC. | $754.85 | 2019-2024 | Synthroid |
| Janssen Pharmaceuticals, INC | $752.10 | 2019-2022 | |
| Amarin Pharma, INC. | $680.58 | 2019-2022 | |
| Abbott Laboratories | $620.43 | 2019-2024 | Freestyle Libre |
| Radius Health, INC. | $584.90 | 2019-2024 | Tymlos |
| Bayer Healthcare Pharmaceuticals INC. | $539.94 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $424.90 | 2019-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $318.32 | 2019 | |
| Medtronic Minimed, INC. | $242.86 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $224.58 | 2022-2023 | Recorlev |
| Mannkind Corporation | $200.09 | 2019-2020 | |
| Insulet Corporation | $167.87 | 2019-2023 | Omnipod |
| Recordati_rare_diseases_inc. | $155.48 | 2023-2024 | Signifor Lar, Isturisa |
| Ibsa Pharma INC. | $143.17 | 2019-2021 | |
| Medtronic, INC. | $124.64 | 2021-2023 | Guardian Connect |
| Amneal Pharmaceuticals LLC | $115.32 | 2021-2023 | Unithroid |
| Halozyme INC | $94.22 | 2023 | |
| Clarus Therapeutics INC. | $91.37 | 2021 | |
| Lundbeck LLC | $80.18 | 2019 | |
| Dexcom, INC. | $79.60 | 2020-2022 | |
| Csl Behring | $63.67 | 2024 | Hizentra |
| Alexion Pharmaceuticals, INC. | $37.30 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $26.98 | 2019-2020 | |
| Acella Pharmaceuticals, LLC | $20.99 | 2022 | |
| Esperion Therapeutics, INC. | $18.61 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.28 | 2019 | |
| Shire North American Group INC | $13.32 | 2019 | |
| Janssen Biotech, INC. | $11.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kolo Ediale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.